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Abstract
Selective serotonin reuptake inhibitors (SSRIs) are commonly prescribed antidepressant drugs in pregnant women.
Infants born following prenatal exposure to SSRIs have a higher risk for behavioral abnormalities, however, the
underlying mechanisms remains unknown. Therefore, we examined the effects of prenatal fluoxetine, the most
commonly prescribed SSRI, in mice. Intriguingly, chronic in utero fluoxetine treatment impaired working memory
and social novelty recognition in adult males. In the medial prefrontal cortex (mPFC), a key region regulating these
behaviors, we found augmented spontaneous inhibitory synaptic transmission onto the layer 5 pyramidal neurons.
Fast-spiking interneurons in mPFC exhibited enhanced intrinsic excitability and serotonin-induced excitability due to
upregulated serotonin (5-HT) 2A receptor (5-HT2AR) signaling. More importantly, the behavioral deficits in prenatal
fluoxetine treated mice were reversed by the application of a 5-HT2AR antagonist. Taken together, our findings
suggest that alterations in inhibitory neuronal modulation are responsible for the behavioral alterations following
prenatal exposure to SSRIs.
Keywords: Prenatal, Serotonin (5-HT), Selective serotonin reuptake inhibitor (SSRI), Fluoxetine, Working memory,
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Introduction
Anti-depressants are commonly prescribed to treat
major depression and post-traumatic stress disorder.
Currently, 17% of pregnant women experience major
depression, and approximately 10% of these women use
anti-depressants [1–3]. The most commonly prescribed
anti-depressants, selective serotonin reuptake inhibitors
(SSRIs), are believed to increase the ambient level of
5-hydrotryptamine (5-HT, serotonin) in synaptic clefts
by preventing its reabsorption [4–6]. However, the exact
mechanism by which SSRIs mitigates depression remains
unknown. A recent systematic review showed that the
potential adverse effects of SSRIs might outweigh their
beneficial effects on depression [7–9]. In addition, fluox-
etine (FLX), one of the most widely used SSRIs with a
moderately long half-life (t ½ = 48 h), can cross the pla-
cental and blood-brain barriers and is also detected in
breast milk, suggesting potential accumulation of FLX as
well as 5-HT in the fetal brain [10]. However, little is
known about the safety of FLX use during pregnancy.
Moreover, the long-term consequences of prenatal FLX
exposure for adverse behavioral outcomes in offspring
are uncertain and sometimes conflicting; these conflict-
ing findings are likely due to the independent association
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between maternal depression and negative pregnancy
outcomes in human [11, 12].
Ansorge et al. firstly observed that postnatal FLX
exposure produced anxiety behaviors and disrupted
learning in rodent offspring [13, 14]. In subsequent
studies, manipulations of brain 5-HT levels during early
development produced abnormal neuronal circuit
formation in the cortex and promoted aggressive or
anxiety-related behaviors [15–19]. However, a thorough
assessment of animal behaviors induced by prenatal
SSRI exposure has not been performed. Furthermore,
the underlying molecular and circuit mechanisms of
these behavioral changes have not been investigated and,
for this reason, no rescue experiment has been per-
formed in offspring exposed to SSRIs during prenatal
period.
Using a combination of behavioral analyses and
electrophysiological investigations of affected neuronal
circuits, we examined how chronic prenatal exposure
to exogenous FLX influences animal behaviors and
neuronal circuitry and function. We observed
impaired social recognition and working memory in
male mice chronically exposed to FLX. Furthermore,
we observed reduced frequencies in spontaneous exci-
tatory postsynaptic currents recorded from layer (L) 5
pyramidal neurons in the prelimbic cortex of affected
mice. Intriguingly, these reduced excitatory neuronal
activities were caused by enhanced serotonergic
modulation of fast-spiking (FS) interneurons in L5
due to enhanced 5-HT2A receptors (5-HT2ARs).
Moreover, the acute treatment with the 5-HT2AR an-
tagonist MDL100907 (MDL) normalized the impaired
social recognition and working memory impairment
in these animals [20].
Results
Prenatal fluoxetine treatment induced deficits in working
memory and social recognition
We subjected pregnant mice to daily intraperitoneal
(i.p.) injections of 0.6 mg/kg FLX or saline (SAL) from
embryonic day (ED) 4 to ED19 to examine behavioral
changes in mice exposed to SSRIs during the prenatal
period (Fig. 1a) [21]. The mean number of pups born
per litter, percentages of male pups per litter, and aver-
age body weights of mice at postnatal day 21 (P21) and
P60 were not significantly different between FLX-treated
litters and SAL-treated, control litters (Table 1). The
FLX-treated mice exhibited normal spontaneous
exploratory behavior in terms of the total distance
traveled (Additional file 1: Figure S1A), but spent less
time in the center zone (t(26) =2.12, p < 0.001; Additional
file 1: Figure S1B), indicating a potential sign of
anxiety-like behaviors. We tested the mice using the
elevated zero maze and light-dark box test to examine
anxiety-like behaviors (Additional file 1: Figures S1C, D).
However, FLX-treated mice did not exhibit differences
in the time spent in the open arms of the elevated
zero maze (Additional file 1: Figure S1C) or total
transitions in the light-dark box (Additional file 1:
Figure S1D), suggesting normal anxiety levels in
FLX-treated mice.
To further examine the role of prenatal FLX in
working memory and cognitive function, we subjected
FLX-treated mice to the Y-maze spontaneous alternation
task [22]. Briefly, both control and FLX treated mice
were allowed to freely access three arms of the Y-maze
for 10 min. Mice prefer to explore a previously
uncharted arm of the maze rather than returning to a
previously visited arm [23]. Intriguingly, the alternation
rate of prenatally FLX-treated mice was lower than that
of SAL-treated mice (t [24] =3.05, p < 0.01; Fig. 1b)
without changes in general activity, as measured by
the total arm entries (p > 0.05; Fig. 1c). To test
whether this reduced alternation rate was due to
either behavioral perseverance or recognition of a
new environment, we performed the novel object
recognition test. Interestingly, both prenatally SAL-
and FLX-treated mice were able to distinguish the
novel and familiar objects, as assessed by the time
spent exploring the novel object (Additional file 1:
Figure S1E). Additionally, there was no significant
difference in grooming behaviors between the two
groups, indicating that the behavioral perseverance of
FLX-treated mice was not associated with repetitive
or obsessive-compulsive behaviors (Additional file 1:
Figure S1F).
Next, we subjected the two groups of mice to the social
interaction test by using a 3-chamber apparatus [25, 26].
During the 10-min habituation phase, neither groups
showed any side preference in the 3-chamber appar-
atus as reflected by the lack of differences in the time
spent sniffing two empty wire pencil holders in the
left and right chambers (p > 0.05; Additional file 1:
Figures S1G, H). Over the next 10 min, both groups
spent significantly more time sniffing the juvenile
male mouse (social stimulus) than the dummy object
(t [9] =7.72, p < 0.001 for SAL; t [9] =10.39, p < 0.001
for FLX; Fig. 1d-f ). During the last 10 min, prenatally
SAL-treated mice spent significantly more time sniff-
ing the novel juvenile male mouse than the familiar
juvenile mouse (t [9] =3.28, p < 0.01), confirming a
preference for social novelty in SAL mice. In contrast,
prenatally FLX-treated mice failed to show this preference,
as indicated by the similar time spent in investigating the
novel and familiar juvenile mice (t [9] = 0.25, p =
0.81; Fig. 1g-i). Taken together, these data indicate
that prenatally FLX-treated mice exhibited deficits in
working memory and social novelty recognition.
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Increased frequency of spontaneous and miniature
inhibitory synaptic currents in layer 5 pyramidal neurons
in the prefrontal cortex of FLX-treated mice
Although the circuit mechanism underlying social
behavior phenotypes observed in prenatally FLX-treated
mice is not obvious [27, 28], the deficits in working
memory observed in the Y-maze spontaneous alternation
task prompted us to characterize neuronal activities in
the prefrontal cortex (PFC), which is functionally analo-
gous to the dorsolateral PFC, a critical area known for
working memory in humans [29]. Within the PFC, infor-
mation is transmitted top-down via pathways from L2/3




Fig. 1 Prenatal exposure to fluoxetine induces deficits in executive functions in male offspring. (a) Schematic diagram of the experimental design.
From embryonic day 4 (ED4) to ED19, pregnant females received daily injections of either fluoxetine (FLX, 0.6 mg/kg/day) or saline (SAL). Male
offspring were subjected to behavioral testing at 8–12 weeks of age. (b) Bar plot of spontaneous alternation rate on the Y-maze. (c) Bar plot of
the total number of entries into all arms of the Y-maze. (d) Representative heat map images of results of the three-chamber social interaction test
with a novel mouse and object. The occupancy rate was normalized to the region with peak occupancy in the arena. (e) Bar plot of the time
spent sniffing the novel mouse and object in the three-chamber social interaction task. (f) Bar plot of the social preference index (time spent
sniffing mouse/total time spent sniffing the mouse and the object). The dotted line indicates an equal preference (50%) (g) Representative heat
map images of the results of the three-chamber social interaction tests with a familiar mouse and novel mouse. (h) Bar plot of the times spent
sniffing the familiar mouse and novel mouse in the three-chamber social interaction task. (i) Bar plot of the social novelty preference index (time
spent sniffing the novel mouse/total time spent sniffing both mice). Data are presented as means ± SEM. (e) and (h) Two-way repeated measures
ANOVA. (b), (c), (f) and (i) Unpaired t-test. * p < 0.05, ** p < 0.01, *** p < 0.001
Table 1 Effects of prenatal SAL and FLX treatment on number,
gender composition and weight of offspring
SAL FLX
Total number of litters 22 23
Total number of offspring 104 96
Total number of male mice 58 49
Average number of pups per litter 4.73 ± 0.44 4.17 ± 0.37
Average number of male pups per litter 2.64 ± 0.33 2.13 ± 0.21
Percentage of male pups in each litter 55.88 ± 4.98% 54.26 ± 4.19%
Weight of male mice at P28 16.44 ± 0.41 g,
n = 20
15.89 ± 0.33 g,
n = 23
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first characterized the morphology of L5 pyramidal neu-
rons, which send the major corticofugal outputs from
the PFC network. We did not observe any differences in
layer formation, the number of neurons, dendritic com-
plexity, and the number of dendritic spines in L5 pyram-
idal neurons between FLX-treated and SAL-treated mice
(Additional file 1: Figure S2). Next, using whole-cell
patch-clamp recordings, we characterized the intrinsic
properties of L5 pyramidal neurons within the prelimbic
area (PrL), which is homologous to the dorsolateral PFC in
primates [30]. We first measured spontaneous excitatory
postsynaptic currents (sEPSCs) in L5 pyramidal neurons
(Fig. 2a-c). The frequency of sEPSCs recorded from
FLX-treated mice was significantly decreased by 18% com-
pared with those recorded from SAL-treated mice, whereas
the amplitude of sEPSCs was unaltered (SAL: 10.46 ± 0.50
Hz, 15.23 ± 0.92 pA; FLX: 8.56 ± 0.51Hz, 15.32 ± 1.45 pA)
(Fig. 2a-c). This indicates that spontaneous excitatory
synaptic transmission in the PFC was decreased in
FLX-treated mice. To further explore the mechanism of
changes in sEPSCs in FLX-treated mice, we recorded
miniature excitatory postsynaptic currents (mEPSCs) and
the neuronal excitability of L5 pyramidal neurons. Intri-
guingly, the frequency and amplitude of mEPSCs recorded
from FLX-treated mice were not significantly different
from mEPSCs recorded from SAL-treated mice (SAL:
6.34 ± 0.60 Hz, 15.61 ± 2.01 pA; FLX: 6.80 ± 0.34Hz,
15.53 ± 1.11 pA) (Fig. 2d-f). More strikingly, most parame-
ters of intrinsic neuronal properties (input resistance,
resting membrane potentials, afterhyperpolarization
amplitude, and the threshold of action potentials (APs)) of
the L5 neurons of FLX-treated mice were not significantly
altered (Additional file 1: Figure S3). These data indicate
that the decreased spontaneous excitatory network
activities did not arise from intrinsic changes in excitatory
neurons in the prefrontal cortex of FLX-treated mice.
To test whether inhibitory synaptic transmission in the
PFC was affected in FLX-treated mice, we recorded both
spontaneous and miniature inhibitory postsynaptic cur-
rents (sIPSCs and mIPSCs, respectively) in L5 pyramidal
neurons within the PrL [30]. Surprisingly, we observed a
significant increase in the frequency of sIPSCs (SAL:
22.46 ± 0.72 Hz; FLX: 29.99 ± 0.96 Hz, p < 0.01), but not
the amplitude (SAL: 36.88 ± 4.57 pA; FLX: 39.29 ± 3.36
pA) (Fig. 2g-i). In contrast, neither the frequency nor the
amplitude of mIPSCs were affected in L5 neurons from
FLX-treated mice (Fig. 2j-l). These data indicate that
prenatal FLX exposure increased spontaneous inhibitory
network activity in L5 pyramidal neurons within the PrL.
Increased excitability and serotonergic modulation of L5
fast-spiking interneurons in PrL of FLX-treated mic
The mPFC receives dense serotonergic innervation from
the raphe nuclei, and both pyramidal and interneurons
within the mPFC express several 5-HT receptor
subtypes, with a particularly high density of 5-HT1A and
5-HT2ARs [31–33]. Chronic increases in ambient
synaptic 5-HT due to SSRI-mediated blockade of the
serotonin transporter (5-HTT) could potentially result
in desensitization, internalization, or compensatory level
changes via transcription and translations of certain
5-HT receptors [24, 34]. To test this hypothesis,
qRT-PCR was performed on the PrL tissues from either
SAL-treated or FLX-treated dams. The qRT-PCR results
showed a significant increase in the levels of the
5-HT2AR mRNAs (SAL vs FLX fold change in 5-HT2AR:
1.49 ± 0.14; p = 0.044, unpaired t-test; SAL, n = 5; FLX, n
= 5). Although not statistically significant, there was an
upward trend in the level of the 5-HT1AR mRNAs (SAL
vs FLX fold change in 5-HT1AR: 1.48 ± 0.17; p = 0.054,
unpaired t-test; SAL, n = 5; FLX, n = 5)(Additional file 1:
Figures S4A, B). In contrast, we did not observe any sig-
nificant changes in the mRNA expression levels of other
5-HT receptors and transporters in both qRT-PCR and
microarray analyses (Additional file 1: Figures S4C, D).
We wondered whether the upregulation of 5-HT 2ARs
resulted in increased spontaneous inhibitory synaptic
transmission in L5 excitatory pyramidal neurons. To ad-
dress this question, we first investigated functional
changes in sIPSCs recorded from L5 pyramidal neurons
upon acute exogenous 5-HT treatment. Consistent with
results from previous studies [35, 36], treatment with
exogenous 5-HT (30 μM) significantly enhanced both
the frequency and amplitude of sIPSCs in L5 pyramidal
neurons in SAL-treated mice by 32.74 ± 6.65% and
29.22 ± 11.09%, respectively (n = 5, p < 0.05, Additional
file 1: Figures S4E, F). Intriguingly, L5 pyramidal neu-
rons in FLX-treated mice exhibited substantial increases
in the frequency and amplitude of sIPSCs (53.25% ± 7.85
and 36.93 ± 6.22%, n = 5, p < 0.05, Additional file 1,
Figures S4E, F).
Next, we recorded the intrinsic excitability and firing
properties of FS inhibitory neurons before and after
5-HT application to further investigate the effects of
5-HT on L5 FS inhibitory neurons that are critical for
shaping cortical circuit activity by projecting their
inhibitory outputs onto the L5 pyramidal neurons within
the PFC [37–39](Fig. 3a). As shown by immunohisto-
chemical staining, the recorded FS interneurons were
positive for parvalbumin (PV) (Fig. 3b) and exhibited a
characteristic 224-Hz firing at a 450pA current injection
(Fig. 3c). Next, we applied a series of incremental square
depolarizing pulses to L5 FS neurons from SAL or FLX
mice before and during 5-HT application (Fig. 3c-g).
5-HT application significantly increased the spike
frequency of L5 FS neurons at each injected current step
in both SAL and FLX mice, and this increase in spike
frequency was normalized after washout. Intriguingly,





Fig. 2 (See legend on next page.)
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compared with L5 FS neurons from the SAL group, L5
FS neurons from the FLX group showed a larger
increase in spike frequency in response to the 5-HT
treatment (SAL: 38.57 ± 5.4% vs FLX: 92.05 ± 17.99%)
(Fig. 3d-g). This increased frequency observed in L5 FS
neurons was abolished by a subsequent treatment with
MDL, a specific antagonist of 5-HT2ARs (1 μM), indi-
cating that the increased responsiveness of 5-HT2AR in
L5 FS neurons resulted in a 5-HT-dependent increase
in AP frequency (Fig. 3d-g). In contrast, co-treatment
with 5-HT1AR antagonists (WAY-100135, 10 μM) and
5-HT did not affect 5-HT-mediated changes in the
spike frequency of L5 FS interneurons (Additional file 1:
Figures S5A-D). Thus, 5-HT-mediated changes in acute
spike frequency were modulated by 5-HT2ARs in the L5
FS interneurons of FLX-treated mice and subsequently
increased sIPSCs in L5 pyramidal neurons.
We further tested the effect of 5-HT treatment on L5
pyramidal neurons. Compared with FS interneurons, L5
pyramidal neurons showed a significantly reduced spike
frequency in response to 5-HT application (Additional
file 1: Figures S6A-C). Furthermore, no significant
difference in the 5-HT-mediated reduction in the sEPSC
frequency in L5 pyramidal neurons was observed
between SAL- and FLX-treated mice (Additional file 1:
Figures S6D, G).
Behavioral deficits of FLX-treated mice were ameliorated
by acute treatment with 5-HT2AR antagonists
Upregulation of 5-HT2AR signaling in PV neurons sup-
pressed spontaneous network firing in L5 PFC microcir-
cuits, resulting in the poor performance of FLX-treated
mice on working memory and social recognition tests.
Therefore, we examined whether the selective suppres-
sion of 5-HT2AR signaling would enhance the perform-
ance of FLX-treated mice in the spontaneous alternation
test and social novelty recognition tests (Fig. 4a). I.P.
injection of a 5-HT2AR antagonist (MDL) did not influ-
ence the general behavior of wild-type animals, when
they tested in the open-field test and elevated zero maze
at a given dosage (data not shown), but the application
of the same dosage of MDL sufficiently reversed
5-HT-mediated changes in the excitability of L5 FS in-
terneurons from FLX-treated mice (Fig. 3g). Intriguingly,
acute administration of MDL effectively reversed the
poor performance of FLX-treated mice on the Y-maze
spontaneous alternation task (Fig. 4b, c). Furthermore,
the acute MDL treatment did not alter the social
preference index in FLX-treated mice (Fig. 4d-f ), but
rescued deficits in the novel recognition task in
FLX-treated mice (Fig. 4g-h). Taken together, our data
revealed that the acute suppression of augmented
5-HT2AR signaling in FLX-treated mice could rescue
their behavioral deficits in working memory and
social recognition memory.
Discussion
We showed that prenatally FLX-treated mice exhibited
deficits in a working memory task and social novelty
recognition paradigm via enhanced inhibitory synaptic
activities in the L5 neurons of the mPFC resulting from
enhanced 5-HT2AR signaling in FS PV neurons. More
importantly, the acute inhibition of 5-HT2AR signaling
in FLX-treated mice successfully reversed the observed
behavioral deficits. Although 5-HT generally plays a
critical role in mammalian neuronal development and
behavior, the causal relationship between alterations in
5-HT homeostasis during pregnancy and adverse behav-
ioral consequences in adulthood is poorly understood.
Previously, several studies have attempted to address this
question using both genetic deletion of SERT and SSRI
administration in rodents. However, these studies suf-
fered from inconsistent behavioral phenotypes, which
were partially due to the use of different rodent strains
and the type, dosage, and timing of administered SSRIs
(see Additional file 1: Table S1). In the present study, we
adopted a treatment scheme similar to that of Noorlander
et al. This treatment mimicked SSRI exposure before the
3rd trimester in humans, in which doctors recom-
mend that pregnant women abstain from (or reduce
the dose of ) SSRIs during late pregnancy [21]. In this
paradigm, we consistently observed behavioral deficits
in Y-maze spontaneous alternation tasks in prenatally
FLX-treated mice without anxiety-related behaviors.
More importantly, SSRI-treated mice exhibited normal
sociability but impaired preference for social novelty
in the three-chamber test (Fig. 1g-i), which is strik-
ingly similar to the behaviors of mice lacking integrin
(See figure on previous page.)
Fig. 2 Fluoxetine induces an increase in the number of inhibitory inputs to excitatory neurons and reduced excitatory basal transmission in the
L5 pyramidal neurons of the prelimbic cortex of FLX-treated mice. (a) Representative current traces depicting spontaneous excitatory post-
synaptic currents (sEPSCs) obtained from L5 pyramidal neurons in the prelimbic cortex (PrL) pyramidal neurons of SAL- and FLX-treated (red)
mice. (b and c) Plots of the cumulative distributions of sEPSC (b) amplitudes and (c) inter-event intervals obtained from SAL- (black) and FLX-
treated (red) mice. (d) Representative current traces depicting mEPSCs obtained from SAL- and FLX-treated mice. (e and f) Plots of the cumulative
distribution plots of mEPSC (e) amplitudes and (f) inter-event intervals. (g) Representative current traces depicting sIPSCs obtained from SAL- and
FLX-treated mice. (h and i) Plots of the cumulative distribution plots of sIPSC (h) amplitudes and (i) inter-event intervals. (j) Representative current
traces depicting mIPSCs obtained from SAL- and FLX-treated mice. (k and l) Plots of the cumulative distribution of mIPSC (k) amplitudes and
(l) inter-event intervals. Data are presented as mean ± SEM. All data were analyzed using the Mann-Whitney U test. *p < 0.05, **p < 0.01
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β3, whose activities are linked to 5-HT transport and
the pathophysiology of hyperserotonemia and autism
[40, 41], as well as other mice lacking genes associ-
ated with autism [42–44].
In contrast to previous studies by Ansorge et al. [13]
and Noorlander et al. [21] we did not find an
anxiety-like effect in adult mice in our experiments. This





Fig. 3 Increased excitability and serotonergic modulation of FS interneurons in PrL of FLX-treated mice. (a) Schematic diagram of the mouse PFC
as outlined by the red dashed lines. The black box indicates a high magnification view of the neurons that were patched. We performed whole-
cell patch-clamp recordings of putative fast-spiking (FS) interneurons in L5 of the PrL. (b) Representative image of a biocytin-filled FS interneuron
in L5. Inset – co-staining for biocytin and parvalbumin, a marker of FS interneurons. (c) Characteristic responses of FS interneurons from SAL-
treated mice to current injections (− 450 pA, 200 pA, and 450 pA) showing low adaptation to repeated firing. (d) Representative traces of FS
interneurons from SAL-treated mice showing responses to current injections (200 pA) at baseline (CTRL), during the bath application of 5-HT
(5-HT), and the bath application of the 5-HT2AR antagonist MDL. (e) Bar plot summarizing the effects of the 5-HT and MDL treatment on FS
interneurons in SAL-treated mice (f) Representative traces of FS interneurons from FLX-treated mice show the responses to current injections
(200 pA) under CTRL, 5-HT and MDL conditions. (g) Bar plot summarizing the effects of the 5-HT and MDL treatments on FS interneurons in
FLX-treated mice. Data are presented as means ± SEM. All data were analyzed using the Wilcoxon signed ranks test. **p < 0.01
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employed postnatal treatment from P4-P21 and the
difference in timeline of exposure to SSRI between the
two protocols could have resulted in different develop-
mental effects on different brain circuits. While the tim-
ing of our protocol was identical to that of Noorlander
et al., [21], the difference in dosage of FLX that was used
(ours: 0.6 mg/kg/day; Noorlander et al.: 0.8 mg/kg/day)
could have different effect on the maturation and/or
modification of emotional brain circuits. Although the
dose difference between two protocols seemed to be
small, Noorlander et al. [21] reported an increased mor-
tality rate of offspring, which we did not observe in ours.
We recorded spontaneous synaptic activities induced
by local inhibitory and excitatory networks in single neu-
rons within L5, a major output neuronal layer within the
mPFC. A significant increase in the frequency of sIPSCs
was observed in the mPFC of FLX-treated mice com-
pared with that in SAL-treated mice (Fig. 2g-i), but the
frequency of sEPSCs recorded in the same neurons was




Fig. 4 Prenatal FLX-induced deficits in executive function are rescued by a 5-HT2AR antagonist. (a) Schematic diagram of the drug treatment
procedure. Prenatally SAL-treated mice were injected with vehicle (VEH), whereas prenatally fluoxetine (FLX)-treated mice were randomly
assigned to VEH and 5-HT2AR antagonist (MDL) groups. Thirty minutes before behavioral testing, FLX mice received i.p. injections of either vehicle
(0.5% DMSO) or MDL (0.01 mg/kg in 0.5% DMSO). (b) Bar plot of spontaneous alternation rates of SAL-treated mice that were administered VEH
(black) and FLX-treated mice that were administered VEH (red) or MDL (blue) in the Y-maze. (c) Bar plot of the total number of entries into all
arms of the Y-maze. (d) Representative heat map of results of the three-chamber social interaction test with a novel mouse and object. The
occupancy rate was normalized to the region with peak occupancy in the arena. (e) Bar plot of the times spent sniffing the novel mouse and
object in the three-chamber social interaction task. (f) Bar plot of the social preference index (time spent sniffing the mouse/total time spent
sniffing the mouse and the object). The dotted line indicates an equal preference (50%) (g) Representative heat map of results from the three-
chamber social interaction test with a familiar mouse and novel mouse. (H) Bar plot of the times spent sniffing the familiar mouse and a novel
mouse in the three-chamber social interaction task. (i) Bar plot of the social novelty preference index (time spent sniffing the novel mouse/total
time spent sniffing both mice). Data are presented as mean ± SEM. (e) and (h) Two-way repeated measures ANOVA. (b), (c), (f) and (i) One-way
ANOVA. * p < 0.05, ** p < 0.01, *** p < 0.001
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were recorded in the same L5 pyramidal neurons, these
data indicate that the ratio of excitatory to inhibitory
drive onto those neurons is abnormally low in
FLX-treated mice. As increase in sIPSC frequency is
caused by activity-dependent changes such as excitabil-
ity, we next blocked APs in a slice with TTX and re-
corded mIPSCs in L5 pyramidal neurons. Intriguingly,
significant differences in both frequency and amplitude
of mIPSCs were not observed between FLX- and
SAL-treated mice, indicating that the increased fre-
quency of inhibitory currents observed in L5 mPFC neu-
rons was due to activity-dependent GABAergic release.
Because these excitatory neurons received inhibitory
synaptic inputs from PV-positive FS interneurons, we
measured the intrinsic excitability of L5 FS interneurons
and observed a significant increase in intrinsic excitabil-
ity without marked changes in channel properties or
input resistance (Additional file 1: Figure S3). We rea-
soned that the compensatory augmentation of specific
5-HT receptors could arise from prolonged exposure to
5-HT due to SSRI treatment and observed a concurrent
increase in two 5-HT receptors, 5-HT1AR and 2AR, using
qPCR analysis. Because of the lack of suitable antibodies
against 5-HT receptors for immunohistochemical ana-
lyses, we performed electrophysiological recordings and
pharmacology to test the contribution of the increased
abundance of specific 5-HT receptors in the PFC of
FLX-treated mice. Surprisingly, increases in activity- and
5-HT-dependent changes in the excitability of FS inter-
neurons were mediated by 5-HT2ARs, but not 5-HT1ARs
(Fig. 3d-g and Additional file 1: Figure S5). Although we
do not clearly understand why 5-HT2AR signaling or ex-
pression was enhanced specifically in FS interneurons,
Athilingam et al. recently showed that 5-HT treatment
in FS interneurons resulted in the suppression of an
inward-rectifying potassium conductance, which eventu-
ally lead to increased excitability of these interneurons
via 5-HT2ARs [45], which might explain the excitability
change in FS interneurons upon chronic SSRI treatment.
Changes in sIPSC frequency or altered inhibitory drive
relative to excitatory drive have been observed in other
animal models of neurodevelopmental disorders in
which working memory deficits have also been reported
[29, 46–48]. Our findings support the hypothesis that
environmental changes induced by a single drug during
pregnancy elicits an imbalance in the inhibitory/excita-
tory drive onto major output neurons in the L5 micro-
circuits within the PFC and subsequently alters animal
behavior through non-genetic, compensatory upregula-
tion of unique classes of 5-HT receptors in specific
neuronal types. However, the potential mechanism of
this compensatory 5-HT-receptor upregulation in FS in-
terneurons needs to be addressed. Furthermore, studies
to determine whether L2/3 neurons in the mPFC or
hippocampal neurons exhibit comparable changes in the
intrinsic excitability of neurons and excitatory/inhibitory
(E/I) imbalance in the network will be interesting. Our
data also support the findings from recent optogenetic
studies showing that acute modulation of the excitability
of FS PV-positive interneurons within the mPFC elicits
changes in network oscillation and the performance of
cognitive flexibility behavior in mice [49, 50]. Therefore,
measurements of network oscillations in FLX-treated
mice during working memory or social novelty task
using in vivo multi-electrode recordings will be exciting.
The increased 5-HT2AR-mediated changes in the
excitability of FS interneurons in FLX-treated mice
prompted us to test whether the behavioral deficits of
these mice were modulated by the application of a
5-HT2AR antagonist, such as MDL. The impairments of
working memory and social novelty recognition were
rescued by an in vivo treatment with MDL (Fig. 4 b-i). It
is intriguingly, because a MDL treatment rescues atten-
tional performance deficits in phencyclidine-treated [51]
and NMDAR antagonist-treated [52] rats. Because pa-
tients with schizophrenia, who usually exhibit working
memory deficits, have very high 5-HT2AR occupancy in
the frontal cortex [53], the enhanced 5-HT2AR activity
observed in our study may represent a general patho-
genic mechanism of behavioral deficits in some mental
disorders, and systemic administration of MDL might
potentially restore synaptic and behavioral deficits in pa-
tients with disorders with similar etiologies.
Taken together, our data revealed that altered prenatal
5-HT homeostasis results in mPFC-dependent behav-
ioral deficits, and systemic modulation of the augmented
5-HT2AR sufficiently rescues these behavioral deficits.
Furthermore, our findings may potentially provide new
opportunities for the pharmacological treatment of pa-
tients who have been prenatally exposed to psychotropic
medications during the prenatal period.
Materials and methods
Animals
Animals were housed in a specific pathogen-free
facility maintained below 22 °C and 55% humidity
under a 12-h light-dark cycle (lights on at 0700 h)
with food and water provided ad libitum [54]. Timed
pregnancy was achieved by breeding wild-type
C57BL6J (The Jackson Laboratory) male mice with
female mice.
Immunohistochemistry
Mice were perfused with PBS, followed by 4% (w/v)
paraformaldehyde in PBS (pH 7.4). Brains were
harvested and fixed with 4% paraformaldehyde overnight,
transferred to 30% (w/v) sucrose in PBS, and then cryosec-
tioned into 40 μm thick slices. For immunohistochemistry,
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brain slices were permeabilized with 0.2% Triton X-100 in
PBS for 10min and transferred to blocking buffer (5%
donkey serum, 2% BSA and 0.2% Triton X-100 in PBS) for
1 h at room temperature. Next, the sections were incu-
bated with primary antibody for parvalbumin (1:1000 di-
luted in blocking buffer, PV-235, Swant) overnight at 4 °C.
The sections were subsequently incubated with appropri-
ate secondary antibodies (1:500 diluted in blocking buffer,
anti-streptavidin Alexa Fluor 488, anti-mouse Alexa Fluor
555; Invitrogen) for 2 h at room temperature. All sections
were then stained with DAPI (1:5000 diluted with 0.2%
Triton X-100 in PBS, Sigma-Aldrich) and mounted with
Fluorsafe (Merck Millipore). Images were captured using
an LSM 710 confocal microscope (Zeiss).
Electrophysiology
L5 neurons were studied in acute coronal slices of the
medial prefrontal cortex (mPFC) from male postnatal
day 90–150 mice. After the mice were anesthetized by
inhalation of 5% isoflurane, they were decapitated, and
their brains were quickly removed and chilled in
ice-cold, high-magnesium cutting solution containing
the following components (in mM): 110 ChCl, 26
NaHCO3, 3.2 KCl, 0.5 CaCl2, 7 MgCl2, 1.25 NaH2PO4,
10 glucose, 2 sodium pyruvate, and 3 ascorbate [55].
The pH was adjusted to 7.4 by saturation with carbogen
(95% O2 and 5% CO2), and the osmolality was approxi-
mately 300 mOsmol/L. The isolated brain was glued
onto the stage of a vibrating blade Compresstome
(VF-200, Precisionary), and 300 μm-thick slices were cut.
The slices were incubated at 34 °C for 30 min in the
same solution and thereafter maintained at room
temperature. For experiments, we transferred a slice that
recovered for at least one hour to a recording chamber
superfused with artificial cerebrospinal fluid (aCSF) con-
taining the following components (in mM): 124 NaCl,
26 NaHCO3, 3.2 KCl, 2.5 CaCl2, 1.3 MgCl2, 1.25
NaH2PO4, and 10 glucose. The aCSF was bubbled with
95% O2 and 5% CO2. Whole-cell voltage- or
current-clamp recordings (one cell per slice) were per-
formed at 32 ± 1 °C, and the rate of aCSF perfusion was
maintained at 1–1.5 ml min− 1. Recordings were per-
formed in somata with a Multiclamp 700B amplifier.
Patch pipettes for current-clamp mode were filled with
internal solutions containing the following components
(in mM): 115 K-gluconate, 20 KCl, 10 Na2-phosphocrea-
tine, 10 HEPES, 2Mg-ATP, 0.3 NaGTP, and 0.1% biocy-
tin. For voltage-clamp recordings, we used internal
solutions containing the following components (in mM):
120 Cs-methane sulfonate, 10 CsCl, 10 TEA-Cl, 1
MgCl2, 10 HEPES, 0.1 EGTA, 0.4 Tris-GTP, 3Mg-ATP,
and 5 Na2-phosphocreatine. We recorded series resist-
ance throughout the experiments and excluded neurons
with series resistance > 20MΩ from data analysis.
Membrane potential values were presented as recorded
without correcting for liquid junction potentials.
MDL10090, CNQX, APV, picrotoxin, and TTX were
purchased from Tocris Bioscience. All other drugs were
purchased from Sigma-Aldrich. Stock solutions of drugs
were made by dissolving in deionized water or DMSO
according to manufacturer’s specifications and were
stored at − 20 °C. On the day of the experiment, one ali-
quot was thawed and used. The concentration of DMSO
in solutions was maintained at 0.1%.
Behavioral assays and analyses
Animals and fluoxetine treatment
Male and female mice breeders were co-housed until
pregnancy. The date when a plug was first noted was
classified as ED0. From ED4 to ED19, pregnant females
were housed individually and received daily i.p.
injections of either FLX (0.6 mg/kg/day in a volume of
10 ml/kg, Sigma) or equal volumes of SAL [21]. Females
used for injection were used only once to minimize the
potential cross-generation effects of FLX administration.
At postnatal day 21–23, offspring were weaned and
housed with their same-sex littermates.
Behavioral assays
For behavioral testing, we used adult males treated
prenatally with either FLX or SAL. All animals were 12
weeks old at the time of testing. All tests except for the
open-field test were conducted during the light phase.
All behavioral apparatuses were cleaned with 70%
ethanol and dried with tissue between each animal.
Open-field test
The open-field test was conducted to measure general
exploratory behavior. Mice were placed into the center
of a Plexiglas cage (40.5 cm × 40.5 cm × 16 cm) for a
60-min test. Horizontal locomotion (i.e., distance
traveled) was automatically recorded and analyzed by
using Versamax software (AccuScan Instruments Inc).
Elevated zero maze
Anxiety-related behavior was measured using the ele-
vated zero maze (CSI-MZ-ZR, Cleversys), which consists
of a circular runway subdivided into two closed and two
open sections elevated 60 cm above the floor. Mice were
initially introduced into one of the closed runways and
were allowed to freely explore the apparatus for 10 min.
During the 10-min test, the percentage of time spent on
the open arms and the number of transitions between
two closed arms were scored using Topscan software
(Cleversys).
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Y-maze test
To allow the mice to discriminate between the three
arms of the Y-maze apparatus (San Diego Instruments),
the sides of one arm of was lined with a pattern of black
vertical bars on a white background with a black square
at the end. The sides of another arm were lined with a
pattern of solid circles with black triangles on a white
background and a triangle marking the end. The
remaining arm was not marked. The Y-maze test was
conducted for 10 min. The first minute was not coded
and treated as the habituation period. Subsequently, the
entries into each arm were recoded. The spontaneous
alternation index was calculated as the number of
non-repeating triplets (for example, if each arm was
labeled “A”, “B” or “C”, “ABCAC” = 2) divided by the
total number of possible non-repeating triplets (total
number of entries into each arm - 2).
Novel object recognition test
The novel object recognition test was conducted in the
open-field apparatus, which was subdivided equally into
two arenas with a red plastic divider. For training, two
identical objects constructed out of Lego blocks were
placed at either end of the arena. Mice were allowed to
explore and familiarize themselves with the two objects
for 10 mins. They were returned to their cages for 20
min while the arena and the objects were cleaned to re-
move any odor cues. Afterwards, a test of short-term
memory was conducted by placing the familiar object
and a novel object that differed in shape, color, and size
at either end of the arena. The duration of sniffing and
bouts of sniffing were manually recorded using Topscan
software (CleverSys).
Social cognition tests
Social preference and social recognition were tested using
a three-chamber apparatus (CSI-SO-PP, CleverSys). The
entire test consists of three consecutive 10min blocks. For
the first block, mice were habituated to the entire appar-
atus and two empty wire pencil holders placed at opposite
corners. For the second block, one juvenile male mouse
(social stimulus) was placed in one holder, and a dummy
object (non-social stimulus) was placed in the other
holder to test for social preference. For the last block, the
juvenile mouse remained in one holder (familiar), but the
dummy object was replaced by a novel juvenile male
mouse (novel) to test for social discrimination.
Golgi staining and tracing
Mice were perfused with PBS and placed in impregna-
tion solution (FD Rapid Golgi-Stain Kit, FD Neurotech)
for one week. 100 μm sections were cut on a cryostat,
processed using the kit’s standard staining procedure
and images were taken with the confocal microscope.
Z-stack images were traced and analyzed with the
Simple Neurite Tracer plugin for ImageJ.
Gene expression study
Total RNA was extracted from punched samples of the
mPFC using an RNeasy kit (Qiagen) followed by cDNA
synthesis using a Quantitect Reverse Transcription kit
(Qiagen). Real-time polymerase chain reaction (PCR)
was performed on three independent sets of templates
using iQ SYBR Green Supermix (Bio-Rad). The amplifi-
cation mixture consisted of 1 μM primers, 10 μl of iQ
SYBR Green Supermix (Bio-Rad), and 100 ng of template
DNA in a total volume of 20 μl. Cycling parameters were
95 °C for 15 s, 57 °C for 1 min and 72 °C for 40 cycles
using a CFX96 real-time PCR detection system
(Bio-Rad). For each assay, PCR was performed after
melting curve analysis. To reduce variability, we ran
each sample in duplicate and included control qPCR
reactions without the template in each run.
For microarray analyses, we normalized all micro-
array data using RMA method provided by the affy
package [56] and analyzed differentially expressed
genes using the limma package [57]. For gene-probe
mapping information and GO term annotation, we
used the EnsEMBL database (version 90).
Statistical analyses
Data were analyzed and plotted using GraphPad Prism
(GraphPad Software) and are presented as the means ±
SEM with symbols representing individual subjects. Data
from the open-field test data were analyzed using
two-way repeated-measures ANOVA, followed by
Tukey’s post hoc test. The rest of the data were analyzed
using the Mann-Whitney test, Wilcoxon Signed rank
test, and unpaired t-test. P < 0.05 was considered statisti-
cally significant. In addition, extreme values were sub-
jected to Grubb’s test for outliers (http://graphpad.com/
quickcalcs/Grubbs1.cfm) and excluded from the analysis.
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